Show simple item record

dc.contributor.authorCumplido-Mayoral, Irene
dc.contributor.authorBrugulat-Serrat, Anna
dc.contributor.authorSánchez-Benavides, Gonzalo
dc.contributor.authorGonzález-Escalante, Armand
dc.contributor.authorAnastasi, Federica
dc.contributor.authorMilà-Alomà, Marta
dc.contributor.authorLópez-Martos, David
dc.contributor.authorAkinci, Muge
dc.contributor.authorFalcón, Carles
dc.contributor.authorShekari, Mahnaz
dc.contributor.authorCacciaglia, Raffaele
dc.contributor.authorArenaza-Urquijo, Eider M
dc.contributor.authorMinguillón, Carolina
dc.contributor.authorFauria, Karine
dc.contributor.authorMolinuevo, José Luis
dc.contributor.authorSuárez-Calvet, Marc
dc.contributor.authorGrau-Rivera, Oriol
dc.contributor.authorVilaplana, Verónica
dc.contributor.authorGispert, Juan Domingo
dc.date.accessioned2024-07-03T08:34:10Z
dc.date.available2024-07-03T08:34:10Z
dc.date.issued2024-04
dc.identifier.citationLancet Healthy Longev. 2024 Apr;5(4):e276-e286.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19925
dc.description.abstractBACKGROUND Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. METHODS In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. FINDINGS Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. INTERPRETATION Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. FUNDING La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. TRANSLATION For the Spanish translation of the abstract see Supplementary Materials section.es_ES
dc.description.sponsorshipThis publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer’s disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), cofunded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/ AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020- 119556RA-I00). OG-R receives funding from the Alzheimer’s Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAlzheimer Disease es_ES
dc.subject.meshCognitive Dysfunction es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshAged es_ES
dc.subject.meshCohort Studies es_ES
dc.subject.meshLongitudinal Studies es_ES
dc.subject.meshPositron-Emission Tomography es_ES
dc.subject.meshNeuropsychological Tests es_ES
dc.subject.meshNeuroimaging es_ES
dc.subject.meshBrain es_ES
dc.subject.meshRisk Factors es_ES
dc.titleThe mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID38555920es_ES
dc.format.volume5es_ES
dc.format.number4es_ES
dc.format.pagee276es_ES
dc.identifier.doi10.1016/S2666-7568(24)00025-4es_ES
dc.contributor.funderFundación La Caixa es_ES
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) es_ES
dc.contributor.funderUnión Europea. Comisión Europea. H2020 es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMarie Curie es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderMinisterio de Ciencia y Universidades (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2666-7568es_ES
dc.relation.publisherversion10.1016/S2666-7568(24)00025-4es_ES
dc.identifier.journalThe lancet. Healthy longevityes_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/ERC/948677es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/847648es_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/100010434es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/LCF/PR/GN17/50300004es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SGR/009132017-SGR-892es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI19/00155es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/LCF/BQ/PR21/11840004es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2018-026053-Ies_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-111514RA-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2020-116907RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC-2013-13054es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-102261es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2020-119556RA-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI19/00117es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/IJC2020-043417-Ies_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional